Enclomiphene Telehealth Providers and Pricing

Direct answer

RightFit now tracks enclomiphene telehealth programs from Mochi Health, Henry Meds, IViM Health, Hone Health, and Maximus. The market spans medication-plus-membership, bundled care, and multi-month subscription models. Hone publishes enclomiphene medication pricing separately from its required hormone-care membership, while Maximus publishes one-, three-, six-, and twelve-month plan rates. RightFit keeps the medication, care fee, labs, plan term, and compounding status separate.

Current enclomiphene telehealth market snapshot

Mochi currently publishes a medication price plus membership

Mochi’s current enclomiphene page publishes a starting medication amount for an oral compounded product while requiring a separate Mochi membership. RightFit therefore keeps the medication price outside the membership rather than presenting the medication amount as the complete recurring program cost.

The current Mochi record also notes that medication availability and pricing can vary by state. RightFit preserves that qualifier instead of treating the published starting amount as a universal nationwide offer.

Henry Meds bundles enclomiphene into its hormone-care program

Henry Meds currently lists compounded enclomiphene capsules as one option inside its TRT program. The structured RightFit record includes the medication, clinician access, shipping, and laboratory work in the tracked monthly program amount. That commercial model differs from Mochi’s separate medication-plus-membership structure.

IViM verifies the product but not a public price

IViM’s current men’s hormone-health page verifies enclomiphene options and baseline laboratory requirements, but RightFit does not currently have a sufficiently clear public medication price for the IViM enclomiphene program. The correct public value is therefore unknown, not zero.

This is an important data-quality rule: verifying that a provider offers a treatment does not justify importing a price from an older promotion, user report, or unrelated checkout flow.

FDA’s compounding list needs careful interpretation

FDA’s current materials on bulk drug substances used in compounding explain that some nominated substances remain under evaluation within the 503A framework. Enclomiphene citrate appears in that evaluation category. Inclusion there does not mean FDA has approved an enclomiphene product for marketing.

FDA’s earlier regulatory record also documents a new drug application for enclomiphene citrate that received a Complete Response rather than marketing approval. RightFit should therefore avoid language that presents current compounded enclomiphene programs as FDA-approved enclomiphene medicines.

Provider claims should remain attributed

Enclomiphene telehealth pages can market the treatment around testosterone support, fertility-related goals, energy, body composition, or other hormone-related outcomes. RightFit can describe what a provider says its program is intended to address, but those statements remain provider claims and are not converted into independent conclusions about effectiveness.

Enclomiphene and testosterone therapy are not one product category

Some telehealth companies place enclomiphene inside a broader men’s hormone or TRT program. That organizational choice does not make compounded enclomiphene the same product as testosterone replacement. RightFit keeps the active ingredient, formulation, preparation type, program price, and source separate.

Laboratory requirements can affect the program structure

Hormone-health programs can publish baseline or follow-up laboratory requirements. Henry’s tracked enclomiphene program includes labs in the program amount, while IViM’s current page verifies baseline laboratory requirements without a published medication price in RightFit. The lab field therefore needs provider-specific evidence.

A known product with an unknown price should remain useful

An unknown price is still a meaningful catalog state. It tells the reader that RightFit has verified the provider and treatment but has not found a current public price that meets the publication standard. That is more transparent than hiding the provider entirely or filling the gap with a stale number.

What to compare across enclomiphene programs

• Exact provider and compounded oral formulation.
• Published medication or program price when verified.
• Separate membership or recurring care fee.
• Whether clinician access and shipping are included.
• Whether baseline or follow-up labs are included or required.
• Program-specific state availability when verified.
• Whether the provider combines enclomiphene with another active ingredient in a separate product.
• Provider-owned source and last-verification date.
• Current FDA compounding-status context kept separate from provider marketing.

What RightFit will not infer

• A 503A bulk-substance evaluation is not treated as FDA approval.
• A lower price does not establish better clinical value.
• A provider’s testosterone or fertility claim is not adopted as an independent effectiveness conclusion.
• An unpublished IViM price is not treated as zero.
• A compounded enclomiphene product is not merged with testosterone therapy.
• A public dose option is not converted into individualized dosing advice.
• A provider’s broad telehealth footprint is not assumed to prove nationwide product availability.

Combination products need separate records

IViM currently advertises enclomiphene options that can also appear in combinations with tadalafil. A combination product should not be merged into a standalone enclomiphene price or product record. The additional active ingredient changes the product being compared and requires its own source and commercial terms.

Why source hierarchy matters

RightFit favors a current provider treatment page for the commercial offer and FDA materials for regulatory status. An old advertisement, search snippet, or user report should not override a current provider page, and a provider page should not override FDA when describing whether a product is approved.

Questions a reader can use

• Is the product compounded enclomiphene or a combination formulation?
• What is the verified medication or program price?
• Is a separate membership required?
• Are labs included or separately required?
• Are clinician access and shipping included?
• Does the price vary by state or plan?
• Is the exact product available in the relevant state?
• Does the provider make outcome claims that should be read as provider marketing?
• When was the provider source last verified?

What this comparison cannot decide

A public program comparison cannot determine whether enclomiphene is appropriate for an individual, whether it should be chosen instead of another hormone-related treatment, or what monitoring or amount is appropriate. Those are clinical decisions that require individualized evaluation by a licensed healthcare professional.

Bottom line

Current enclomiphene telehealth programs differ meaningfully in pricing disclosure, membership structure, laboratory requirements, and commitment length. Mochi, Henry Meds, IViM, Hone Health, and Maximus now illustrate several commercial models, from medication-plus-membership to bundled and multi-month subscriptions. RightFit keeps those differences visible while separating compounded enclomiphene from FDA drug approval and from testosterone-replacement products.

Compounding status can change without changing the provider’s marketing name

The regulatory framework for compounded products can evolve independently of a provider’s commercial page. FDA can update its bulk-substance categories, enforcement approach, or other compounding guidance while a telehealth provider continues to use the same enclomiphene product name. RightFit therefore rechecks FDA sources separately from provider pricing sources rather than assuming a stable marketing name means stable regulatory context.

Provider program structure can change faster than the treatment label

A provider can revise membership pricing, laboratory requirements, included care, or state availability without renaming the enclomiphene program. That is why RightFit stores the source and verification date with each commercial fact. A future price change should update the relevant field rather than rewriting unrelated product or regulatory information.

The price-unknown state protects the catalog from false precision

IViM demonstrates why RightFit needs an explicit unknown state. The treatment and product options are visible, but a current public medication price is not sufficiently verified. Publishing a guessed or stale number would make the catalog look more complete while making it less accurate. The unknown state keeps the provider discoverable without overstating the evidence.

Regulatory and commercial sources answer different questions

The provider source can establish that a company advertises compounded enclomiphene, the product options it lists, and the current program structure. FDA materials establish the federal compounding context and regulatory history. RightFit keeps those source roles separate so provider marketing cannot be mistaken for regulatory approval and regulatory documents are not misused to invent a provider price.

Why unknown pricing should remain visible in the provider comparison

A provider with a verified enclomiphene program but no current public price still belongs in the market view. Showing that record as price unknown distinguishes “not offered” from “offered but not publicly priced.” It also prevents stale promotions or third-party reports from being promoted into the catalog simply to make every row look complete. That conservative approach makes later price verification easier because a newly published first-party amount can be added cleanly when it appears.